Literature DB >> 3129438

Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin.

C A Hébert1, J B Baker.   

Abstract

Several cell types display binding sites for [125I]urokinase (Vassalli, J.-D., D. Baccino, D. Belin. 1985. J. Cell Biol. 100:86-92) which in certain cases are occupied with endogenous urokinase. These sites appear to focus urokinase at cell surfaces and hence may participate in tissue matrix destruction and cell invasion. Recently Pöllänen et al. (1987) demonstrated that the cell surface urokinase of human fibroblasts and fibrosarcoma cells is deposited underneath the cells in strands, apparently at sites of cell-to-substratum contact. Here, using immunofluorescence double labeling, we show that the urokinase strands present on human foreskin fibroblasts are colocalized with strands of vinculin, an intracellular actin-binding protein that is deposited at cell-to-substratum focal adhesion sites. Thus, this indicates linkage of the plasminogen/plasmin system both to sites of cell adhesion and to the cytoskeleton. The urokinase strands on HT 1080 fibrosarcoma cells are more numerous and have shapes that are more tortuous than those on normal fibroblasts. In intact HT 1080 cells, colocalized vinculin strands are obscured by an intense background of soluble vinculin but are apparent on isolated ventral plasma membranes. Certain properties of the urokinase strands suggest that they are related to the [125I]urokinase-binding sites that have been described by several groups: (a) incubating fibroblasts with dexamethasone for 48 h or at pH 3 at 5 degrees C for 10 min greatly decreases the number and intensity of the urokinase strands; (b) strands reappear when glucocorticoid-treated cells are incubated with exogenous 54-kD (but not 35-kD) urokinase, and this process is inhibited by a previously described 16-amino acid peptide that blocks [125I]urokinase binding to the cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129438      PMCID: PMC2115021          DOI: 10.1083/jcb.106.4.1241

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  30 in total

1.  Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.

Authors:  J P Quigley; L I Gold; R Schwimmer; L M Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue.

Authors:  L Ossowski; D Biegel; E Reich
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

3.  The locomotion of fibroblasts in culture. IV. Electron microscopy of the leading lamella.

Authors:  M Abercrombie; J E Heaysman; S M Pegrum
Journal:  Exp Cell Res       Date:  1971-08       Impact factor: 3.905

4.  A 130K protein from chicken gizzard: its localization at the termini of microfilament bundles in cultured chicken cells.

Authors:  B Geiger
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

5.  Molecular species of plasminogen activators secreted by normal and neoplastic human cells.

Authors:  E L Wilson; M L Becker; E G Hoal; E B Dowdle
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

6.  Substrate-attached membranes of cultured cells isolation and characterization of ventral cell membranes and the associated cytoskeleton.

Authors:  Z Avnur; B Geiger
Journal:  J Mol Biol       Date:  1981-12-05       Impact factor: 5.469

7.  Microinjection and localization of a 130K protein in living fibroblasts: a relationship to actin and fibronectin.

Authors:  K Burridge; J R Feramisco
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

8.  Plasminogen activator (urokinase) causes vascularization of the cornea.

Authors:  M Berman; S Winthrop; D Ausprunk; J Rose; R Langer; J Gage
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-02       Impact factor: 4.799

9.  Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities.

Authors:  A Raz; B Geiger
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

10.  Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.

Authors:  K Hashimoto; K M Shafran; P S Webber; G S Lazarus; K H Singer
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Differential roles of multiple adhesion molecules in cell migration: granule cell migration in cerebellum.

Authors:  C M Chuong
Journal:  Experientia       Date:  1990-09-15

2.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

3.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

4.  Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.

Authors:  J Hagège; M N Peraldi; E Rondeau; C Adida; F Delarue; R Medcalf; W D Schleuning; J D Sraer
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

5.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

6.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

7.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.

Authors:  C Festuccia; V Dolo; F Guerra; S Violini; P Muzi; A Pavan; M Bologna
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

9.  In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.

Authors:  E Bacharach; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.